default author photo

Wilbert Zwart

Netherlands Cancer Institute - Division of Oncogenomics

Plesmanlaan 121

Amsterdam, 1066 CX

Netherlands

Oncode Institute

Utrecht

Netherlands

Eindhoven University of Technology (TUE) - Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering

Eindhoven

Netherlands

SCHOLARLY PAPERS

3

DOWNLOADS

211

TOTAL CITATIONS

2

Scholarly Papers (3)

1.

AR Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Number of pages: 28 Posted: 30 Mar 2023
University of California, San Francisco (UCSF), Oregon Health and Science University - Knight Cancer Institute, Oregon Health and Science University - Department of Cell, Developmental and Cancer Biology, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), Oregon Health and Science University - Knight Cancer Institute, Oregon Health and Science University - Knight Cancer Institute, University of California, San Francisco (UCSF), Netherlands Cancer Institute - Division of Oncogenomics, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF) - Department of Urology, University of California, San Francisco (UCSF), Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, Netherlands Cancer Institute - Division of Oncogenomics, University of California, San Francisco (UCSF) - Department of Urology, Columbia University, Center for Cancer Research, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), Netherlands Cancer Institute - Division of Oncogenomics, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), Oregon Health and Science University - Knight Cancer Institute and University of California, San Francisco (UCSF)
Downloads 93 (725,554)

Abstract:

Loading...

prostate cancer, major histocompatibility complex class I, androgen receptor, antigen presentation, immune response

2.

Somatic Mutations and Risk-Variants Converge on Cis-Regulatory Elements to Reveal the Cancer Driver Transcription Regulators in Primary Prostate Tumors

Number of pages: 49 Posted: 07 Sep 2018
University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, Netherlands Cancer Institute - Division of Oncogenomics, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, Netherlands Cancer Institute - Division of Oncogenomics, University of Toronto - Princess Margaret Cancer Centre, Stanford University - Department of Genetics, Ontario Institute for Cancer Research, Ontario Institute for Cancer Research, Ontario Institute for Cancer Research, University of Toronto - Department of Pathology and Laboratory Medicine, Ontario Institute for Cancer Research, University of Toronto - Princess Margaret Cancer Centre, The University of Manchester - Manchester Cancer Research Centre, Netherlands Cancer Institute - Division of Oncogenomics and University of Toronto - Princess Margaret Cancer Centre
Downloads 85 (771,553)
Citation 2

Abstract:

Loading...

3.

Enhancer Profiling Identifies Epigenetic Markers of Endocrine Resistance and Reveals Therapeutic Options for Metastatic Castration-Resistant Prostate Cancer Patients

Number of pages: 88 Posted: 13 Mar 2023
Netherlands Cancer Institute - Division of Oncogenomics, Netherlands Cancer Institute - Division of Oncogenomics, Netherlands Cancer Institute - Division of Oncogenomics, Netherlands Cancer Institute - Division of Oncogenomics, University of Washington - Department of Urology, University of Washington - Department of Urology, Tampere University - Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tays Cancer Centre, VU University Amsterdam - Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Netherlands Cancer Institute - Division of Oncogenomics, Netherlands Cancer Institute - Division of Oncogenomics, Netherlands Cancer Institute - Division of Oncogenomics, Netherlands Cancer Institute - Division of Molecular Carcinogenesis, Netherlands Cancer Institute - Division of Molecular Carcinogenesis, Tampere University - Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tays Cancer Centre, Netherlands Cancer Institute - Department of Biometrics, Netherlands Cancer Institute - Department of Pathology, Netherlands Cancer Institute - Division of Molecular Carcinogenesis, Erasmus University Rotterdam (EUR) - Department of Urology, Erasmus University Rotterdam (EUR) - Department of Pathology, Cancer Institute, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Netherlands Cancer Institute - Division of Molecular Carcinogenesis, Tampere University - Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tays Cancer Centre, Netherlands Cancer Institute - Division of Molecular Carcinogenesis, University of Washington - Department of Urology, Netherlands Cancer Institute - Division of Oncogenomics and Netherlands Cancer Institute - Division of Oncogenomics
Downloads 33 (1,277,121)

Abstract:

Loading...

mCRPC, enzalutamide, epigenetics, androgen receptor, H3K27ac, HDAC inhibitors, biomarkers, hormone intervention